Additional Relevant Details Summary of Results  

• Gout symptom improvements were greatest for responders, but also significant for non-responders.
• 25 percent of non-responders reported complete tophus resolution at six months.
• Non-responders achieved a statistically significant decrease in gout flares at six months.
• Non-responders reported improvements from baseline across several meaningful clinical endpoints including Patient Global Assessment, tender and swollen joints and pain.
• No significant improvements were observed among patients who received placebo.
• Across the pivotal clinical trials, the most common serious side effects in patients taking KRYSTEXXA were gout flare-ups or attacks, severe allergic reactions, and infusion reactions.